Literature DB >> 24935059

Intermediate serrated polyp as an intermediate lesion of hyperplastic polyp and sessile serrated polyp/adenoma in terms of morphological and molecular features.

Hyeong Ju Kwon1, Nam-Yun Cho2, Mee Soo Chang1, Yong Sung Kim3, Gyeong Hoon Kang4.   

Abstract

Although a hyperplastic polyp (HP) shares morphological and molecular features with a sessile serrated adenoma/polyp (SSA/P), HPs and SSA/Ps are considered nonneoplastic and neoplastic epithelial polyps, respectively. Because HPs and SSA/Ps cover the morphological spectrum, we hypothesized that an intermediate serrated polyp (ISP) might exist between an HP and an SSA/P in terms of both morphological and molecular aspects. An ISP was defined as a serrated lesion that carries distorted crypts (columnar crypt dilation, irregularly branching crypts, or horizontally arranged basal crypts) in less than 3 consecutive crypts. We analyzed HPs (microvesicular, n = 16, and goblet cell-rich, n = 28), ISPs (n = 44), and SSA/Ps (n = 26) for their methylation status of 8 CpG island methylator phenotype panel markers and mutation status of KRAS/BRAF. The number of methylated markers and BRAF mutation frequency increased in the order of HP, ISP, and SSA/P. Microvesicular HPs and goblet cell-rich HPs are distinct from each other, based on the high frequency of BRAF and KRAS mutation, respectively, but are not different in the number of methylated panel markers. Proximally located microvesicular HPs and ISPs were higher in the number of methylated markers but lower in the frequency of BRAF mutation than distally located ones. However, SSA/Ps did not show any difference in the number of methylated markers and the frequency of BRAF mutation between proximally and distally located lesions. Our findings that serrated polyps, intermediate between HPs and SSA/Ps in terms of morphological features, display molecular alterations intermediate between those of HPs and SSA/Ps suggest the presence of ISPs between HPs and SSA/Ps.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; CpG island locus; DNA methylation; KRAS; Serrated lesion

Mesh:

Substances:

Year:  2014        PMID: 24935059     DOI: 10.1016/j.humpath.2014.04.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon.

Authors:  Miroslaw Kiedrowski; Andrzej Mroz; Ewa Kraszewska; Alina Rembiszewska; Anna Felisiak-Golabek; Jolanta Kupryjanczyk; Andrzej Deptala; Janina Orlowska
Journal:  Contemp Oncol (Pozn)       Date:  2014-12-31

2.  Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation.

Authors:  Tilman T Rau; Raja Atreya; Daniela Aust; Gustavo Baretton; Matthias Eck; Katharina Erlenbach-Wünsch; Arndt Hartmann; Alessandro Lugli; Robert Stöhr; Michael Vieth; Anna M Wirsing; Inti Zlobec; Tiemo Katzenberger
Journal:  J Pathol Clin Res       Date:  2016-02-25

3.  Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS).

Authors:  Sukanya Horpaopan; Jutta Kirfel; Sophia Peters; Michael Kloth; Robert Hüneburg; Janine Altmüller; Dmitriy Drichel; Margarete Odenthal; Glen Kristiansen; Christian Strassburg; Jacob Nattermann; Per Hoffmann; Peter Nürnberg; Reinhard Büttner; Holger Thiele; Philip Kahl; Isabel Spier; Stefan Aretz
Journal:  Hered Cancer Clin Pract       Date:  2017-11-29       Impact factor: 2.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.